1-7 of 7
Yolanda González, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials

Lucia Lopez-Anglada, MDPhD, Cecilia Cueto-Felgueroso, Maria-Victoria Mateos, Laura Rosiñol, MDPhD, Albert Oriol, MDPhD, Ana Isabel Teruel, MD, Ana Lopez de la Guia, MD, Luis Palomera, MDPhD, Felipe de Arriba, MDPhD, Jose Mariano Hernandez, MD, Miquel Granell, MD, Francisco Javier Peñalver, MD, Ramon Garcia-Sanz, MDPhD, Juan Besalduch, MDPhD, Yolanda Gonzalez, MD, Rafael Martinez, MDPhD, Miguel Teodoro Hernandez, MDPhD, Norma C Gutierrez, Paloma Puerta, MD, Joan Blade, MDPhD, Jesús San Miguel, MDPhD, Juan José Lahuerta, MDPhD, Joaquin Martinez Lopez, MDPhD
Journal: Blood
Blood (2015) 126 (23): 2962.
https://doi.org/10.1182/blood.V126.23.2962.2962
Published: 2015
Journal Articles

Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)

Maria-Victoria Mateos, Norma C Gutierrez, María-Luisa Martín, Joaquín Martínez-López, MD PhD, Miguel T Hernandez, Rafael Martinez, MDPhD, Laura Rosiñol, MDPhD, Enrique M. Ocio, MD PhD, Ana Isabel Teruel, MD, Albert Oriol, MDPhD, Juan Jose Bargay, Enrique Bengoechea, Yolanda Gonzalez, MD, Jaime Perez De Oteyza, Mercedes Gironella, Cristina Encinas, Jesus Martin, Carmen Cabrera, Bruno Paiva, PhD, Noemi Puig, MD PhD, Joan Blade, MDPhD, Juan José Lahuerta, Jesus San Miguel, MDPhD
Journal: Blood
Blood (2015) 126 (23): 4243.
https://doi.org/10.1182/blood.V126.23.4243.4243
Published: 2015
Journal Articles

Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years

Maria-Victoria Mateos, MD PhD, Joaquín Martínez-López, Miguel T Hernandez, Enrique M Ocio, Laura Rosiñol, MDPhD, Rafael Martinez, MD, Ana Isabel Teruel, MD, Norma C Gutierrez, María-Luisa Martín, Albert Oriol, MD, Joan Bargay, MD, Enrique Bengoechea, Yolanda Gonzalez, MD, Jaime Perez de Oteyza, Mercedes Gironella, Cristina Encinas, Carmen Cabrera, Bruno Paiva, PhD, Maria Teresa Cedena, Noemi Puig, MD PhD, Joan Blade, MDPhD, Juan José Lahuerta, Jesus San Miguel, MDPhD
Journal: Blood
Blood (2015) 126 (23): 1848.
https://doi.org/10.1182/blood.V126.23.1848.1848
Published: 2015
Journal Articles

Renal Response in Patients (Pts) with Relapsed Refractory Multiple Myeloma (RRMM): Interim Data of a Large Observational, Prospective Study

Javier de la Rubia, Enrique Morales, Fernando Escalante, Mª Soledad Durán, Manuel Perez Encinas, Merche Gironella, Tomas J Gonzalez-Lopez, Ignacio Español, Josep Sarrà, Elena Cabezudo, Esther Gonzalez, Carmen Calle, Rafael Martinez, Mario Arnao, Yolanda González, MD, José Antonio Márquez, Valentin Cabañas, Joan Blade, Antonio Ruiz Boza, Antonio Garcia
Journal: Blood
Blood (2014) 124 (21): 2104.
https://doi.org/10.1182/blood.V124.21.2104.2104
Published: 2014
Journal Articles

Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity

Daniel Primo, PhD, Joan Ballesteros, PhD, Antonio Jimenez, MD, Ataulfo Gonzalez, MD, Miguel Hernandez, MD, Raul Cordoba, MD, Yolanda González, MD, Hernan Jose Moreno, MD, Alicia Bailen, MD, Jesus Martin, MD, Anabelle Chinea, MD, Asuncion Etxeveste, MD, Jose Mariano Hernandez, MD, Albert Oriol, MD, Jaime Perez de Oteiza, MD, Luis Palomera, Cristina Encinas, MD, Felipe Prosper, MD, Rebeca Iglesias, MD, Laura Rosiñol, MD PhD, Alicia Robles, Julian Gorrochategui, Veronica Garcia, Pilar Hernandez, PhD, Enrique Ocio, MD, Joaquin Martinez, MD
Journal: Blood
Blood (2014) 124 (21): 5785.
https://doi.org/10.1182/blood.V124.21.5785.5785
Published: 2014
Journal Articles

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.

Francesc Bosch, MD, PhD, Pau Abrisqueta, MD, Neus Villamor, MD, PhD, Maria Jose Terol, MD, Josep-Maria Ribera, MD, Eva Gonzalez-Barca, MD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Yolanda Gonzalez, MD, Secundino Ferrer, MD, Felix Carbonell, MD, Lourdes Escoda, MD, Isidro Jarque, MD, Encarnacion Monzo, MD, Ana Muntañola, MD, Olga Salamero, MD, Emili Montserrat, MD
Journal: Blood
Blood (2008) 112 (11): 2097.
https://doi.org/10.1182/blood.V112.11.2097.2097
Published: 2008
Journal Articles

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Francesc Bosch, MD, PhD, Ana Muntañola, MD, Neus Villamor, MD, Maria Jose Terol, MD, Elena Gonzalez-Barca, MD, Josep Maria Ribera, MD, PhD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Felix Carbonell, MD, PhD, Jose A. Garcia-Marco, MD, PhD, Lourdes Escoda, MD, Secundino Ferrer, MD, E. Monzo, MD, Yolanda Gonzalez, MD, Pau Abrisqueta, MD, Olga Salamero, MD, Eva Gine, MD, Emili Montserrat, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 626.
https://doi.org/10.1182/blood.V110.11.626.626
Published: 2007